

20 **Abstract** (227 words)

21 Background: Whether vaccination or natural infection provides greater benefit regarding the
22 development of sustained immunity against SARS-CoV-2 remains unknown. Therefore, the aim
23 of this study was to provide a direct comparison of IgG durability and neutralizing antibody
24 (NAb) levels in vaccinated and unvaccinated adults.

25 Methods: This was a prospective, cross-sectional study of antibody durability in 1087 individuals
26 with a median (IQR) age of 42 (35, 52) years who were unvaccinated and previously infected
27 with SARS-CoV-2 (Arm 1, n=351) or vaccinated against the virus (Arm 2, n=737). Participants
28 self-reported vaccination and infection history and provided self-collected serology samples
29 using mailed collection kits.

30 Results: Anti-S1 IgG seroprevalence was 15.6% higher in vaccinated versus unvaccinated,
31 previously-infected individuals across intervals ranging from 1 to 12 months and antibody
32 survival was sustained near 100% through 12 months in the vaccinated group. NAb titers at 50%
33 inhibition were significantly greater in vaccinated individuals with values that averaged 893.0
34 units higher than those observed in the unvaccinated, naturally infected group.

35 Conclusions: These findings suggest that vaccination as opposed to natural infection alone
36 provides significant advantages in terms of sustained and effective (neutralizing) immunity
37 against prior variants of SARS-CoV-2. Future efforts to characterize SARS-CoV-2 immune
38 responses should address hybrid immunity, booster status and formulation, and protection
39 against (sub)variants of Omicron and future lineages, as well as weigh the potential impact of
40 other immune system mechanisms.

41

42

43 **Introduction**

44 Throughout the course of the Coronavirus Disease 2019 (COVID-19) pandemic, the widespread
45 adoption of vaccination has been promoted for its potential to significantly curtail health and
46 economic burdens related to the spread of SARS-CoV-2, and ultimately, key to bringing the
47 pandemic to an end (1, 2). In less than a year from the World Health Organization (WHO)
48 declaring the pandemic, following an unprecedented development effort, vaccines were available
49 to most adults in western societies. However, vaccination campaigns were met with varying
50 degrees of hesitancy in portions of the population (3-5). In the intervening months, researchers
51 documented Immunoglobulin G (IgG) seroconversion and fluctuating levels of sustained
52 immunity resulting from natural infection and/or vaccination (6-15), and established a positive
53 relationship between anti-spike antibodies and clinical protection from SARS-CoV-2 (16-18).

54
55 However, the current literature does not provide a clear difference in antibody profiles acquired
56 through vaccination and natural infection. This distinction is of renewed importance at a time
57 when nearly 60% of the United States (US) population (including 75% of US children) are
58 reported to show serological evidence of community exposure (19) and the sense of urgency
59 related to vaccination has waned. Despite a growing body of literature, availability of data
60 directly comparing antibody responses following vaccination versus natural infection is limited.
61 Prospective evaluations tend to be limited in sample size (12, 14, 20-22), have short serological
62 monitoring periods,(9, 20, 22) or analyses were completed retrospectively (23, 24). Many studies
63 utilize populations of healthcare workers who may encounter infectious agents – including
64 SARS-CoV-2 – more frequently than other members of the community, limiting generalizability
65 of results due to potential repeated exposures and subclinical infections (9, 12, 20, 25). Several

66 quality studies have evaluated the effectiveness of vaccination- and/or infection-acquired
67 immunity over time, but have lacked a serological component (24-26). Therefore, in the current
68 study, we aimed to provide a direct comparison of IgG durability and neutralizing antibody
69 (NAb) levels in vaccinated and unvaccinated individuals in a prospective US sample. This work
70 presents the largest such comparison in a prospectively-collected, population-wide sample to
71 date.

72

73 **Methods**

74 *Ethics approval and consent to participate*

75 This protocol was approved by WCG IRB (IRB registration #20210763). All participants
76 provided written informed consent prior to enrollment in the study.

77

78 *Study design*

79 This was a prospective, cross-sectional study of antibody durability in individuals who were
80 previously infected with SARS-CoV-2 (Arm 1) or vaccinated against the virus (Arm 2). The
81 study utilized electronic questionnaires and self-collected dried blood spot (DBS) samples to
82 gather data remotely from participants within the US. Upon enrollment, participants answered
83 questions about COVID-19 diagnosis and vaccination history, symptom and treatment
84 information, and other relevant medical history such as comorbid conditions and medication use.
85 Participants received a COVID-19 Antibody Home Collection Kit (Everlywell, Inc., Austin, TX)
86 to provide samples for qualitative IgG detection. Baseline data were captured to complete the
87 primary analysis of comparative IgG durability between study arms. In addition, Arm 2

88 participants repeated questionnaires and serology tests during a follow-up period for up to 9
89 months, facilitating a secondary survival analysis of vaccine-acquired IgG.

90

91 *Participant eligibility and enrollment*

92 Participants were enrolled in the study between March and November 2021. Inclusion criteria for
93 Arm 1 included prior infection with SARS-CoV-2 (evidenced by a positive diagnostic test) and
94 unvaccinated status. Eligibility for Arm 2 required receipt of at least one dose of a SARS-CoV-2
95 vaccine. All participants were required to be age 18 years or older, reside within the continental
96 US, and have access to an email account and internet service. Exclusion criteria included known
97 conditions or ongoing treatments associated with immune impairment (e.g., chemotherapy) and
98 residents of New York state. All participants provided written informed consent prior to
99 enrollment in the study, which was approved by WCG IRB (IRB study #20210763).

100

101 *Serology Testing*

102 DBS samples were self-collected at baseline and follow-up timepoints for serology testing using
103 the Anti-SARS-CoV-2 ELISA Assay (EUROIMMUN, Germany). A subset of samples was
104 subjected to secondary testing using the NAB-Sure™ SARS-CoV-2 Neutralizing Antibody Test
105 (SpearBio, Inc, Woburn, MA).

106

107 *Study Endpoints*

108 The primary endpoint was the expected difference in S1-binding IgG seropositivity between Arm
109 1 (unvaccinated, naturally infected individuals) and Arm 2 (vaccinated individuals) over
110 time. The secondary endpoints included: (1) the difference in expected NAb titer between Arm 1

111 and Arm 2 over time, and (2) S1-binding IgG and NAb survival percentages at 4 and 12 months
112 since last exposure to a vaccine product in Arm 2.

113

114 *Statistical Analysis*

115 Multiple linear regression was used to evaluate the effect size and significance of each study arm
116 (vaccination vs natural infection) on estimated seropositivity over time (binned as the number of
117 months since last vaccine dose or infection). Estimates per study arm per time interval that
118 included fewer than 3 serology values were considered under sampled and dropped prior to
119 analysis.

120

121 Additionally, a discrete-time analysis was conducted using independent z-tests of proportions at
122 1, 3, 6, 9, and 12 months to evaluate differences in seropositivity between Arms 1 and 2. P-
123 values are reported and interpretable using a Bonferroni-adjusted value of 0.005. To further
124 evaluate S1-binding IgG durability associated with vaccination, survival analysis was performed
125 using the Kaplan-Meier method. Percent survival at 4 and 12 months is reported with 95%
126 confidence intervals. This analysis was conducted in two ways, reflecting (1) time from the most
127 recent vaccination dose (i.e., a booster dose reset the interval clock), and (2) time from the initial
128 vaccination dose. For the NAb analysis, as above, the time variable was binned as the number of
129 months since the last vaccine dose or infection. Quantitative NAb titer was similarly evaluated
130 over time, stratified by study arm.

131

132 **Results**

133 *S1-binding IgG Cross-Sectional Analysis*

134 A total of 1,087 participants enrolled in the study and completed all required baseline
 135 assessments for inclusion in the analysis: 351 were assigned to Arm 1 and 737 were assigned to
 136 Arm 2 at baseline. Over three quarters of participants included in the cross-sectional analysis
 137 were female, and the median (IQR) age was 42 (35, 52) years. Over two thirds of vaccinated
 138 participants reported no previous SARS-CoV-2 infection prior to entering the study. Baseline
 139 participant characteristics are summarized in Table 1.

140

141 Table 1: Participant demographics and diagnostic test history

Characteristic	Overall N = 1088	Arm 1 N = 351	Arm 2 N = 737
Sex			
Female	831 (76%)	258 (74%)	573 (78%)
Male	255 (23%)	93 (26%)	162 (22%)
Unknown	2 (0.2%)	0 (0%)	2 (0.3%)
Age			
Median (IQR)	42 (35, 52)	43 (34, 54)	42 (35, 51)
Unknown	2 (0.2%)	0 (0%)	2 (0.3%)
COVID Diagnostic History			
Known Infection	566 (52%)	351 (100%)	215 (29%)
No Known Infection	508 (47%)	0 (0%)	508 (69%)
Unknown/NA	14 (1.3%)	0 (0%)	14 (1.9%)
Vaccine Product			
Ad26.COVS2.s (Johnson & Johnson)	56 (5.1%)	0 (0%)	56 (7.6%)
BNT162b2 (Pfizer)	396 (36%)	0 (0%)	396 (54%)
mRNA-1273 (Moderna)	280 (26%)	0 (0%)	280 (38%)
NVX-CoV2373 (Novavax)	1 (<0.1%)	0 (0%)	1 (0.1%)
Not Applicable	351 (32%)	351 (100%)	0 (0%)
Unknown	4 (0.4%)	0 (0%)	4 (0.5%)

142

143

144 Nearly all Arm 2 participants entered the study fully vaccinated, defined as having received all
 145 doses in the primary series of the applicable vaccine, with only 3.7% reporting partial
 146 vaccination (or only having received one dose of a two-dose primary vaccination regimen) at

147 baseline. No participants reported receiving a booster dose prior to enrollment. The difference in
148 time between participants' most recent confirmed exposure (positive diagnostic test date or
149 vaccination date for Arm 1 or 2, respectively) and baseline serology test date ranged from 1 to 15
150 months (median) after dropping under-sampled time intervals (N=1,007).

151
152 Population-wide seropositivity remained high across time intervals. The seropositivity effect size
153 associated with vaccination was 15.6% greater than the reference arm (Arm 1), independent of
154 time since vaccination (Figure 1 and Table 2).

155

156 Table 2: Difference in seropositivity by exposure mode

Time Interval	Difference in Arm 2 (Vaccinated) versus Arm 1 (Unvaccinated/Natural Infection)	Z-score	p-value
1 month	+11.9%	-28.06	1.37×10^{-173}
3 months	+14.3%	-125.62	0.00
6 months	+15.6%	-66.93	0.00
9 months	+13.5%	-13.58	2.71×10^{-42}
12 months	+11.1%	-4.33	7.34×10^{-6}

157

158 *SI-binding IgG Longitudinal Analysis in vaccinated individuals (Arm 2)*

159 A total of 1,605 samples from 737 vaccinated individuals were available for antibody survival
160 analysis. Antibody survival (with 95% CI) ranged from 99.4% (99.0%-100%) at 4 months to
161 95.5% (91.7%-99.5%) at 12 months when measured in time since the last dose received, and
162 from 99.7% (99.3% - 100%) at 4 months to 98.4% (97.1%-99.7%) at 12 months when measured
163 from the first dose. No further loss of IgG detectability was observed beyond 12 months in either
164 analysis.

165

166 *NAb Cross-Sectional Analysis*

167 One sample from each of 332 individuals was included in the sub-cohort NAb analysis,
168 including 122 Arm 1 (unvaccinated, previously infected) samples and 210 Arm 2 (vaccinated)
169 samples. The sub-cohort was predominantly female (77.1%). The median (IQR) age was 44
170 years in both Arm 1 (37, 55) and Arm 2 (37, 52).

171
172 NAb titers at 50% inhibition (NT50) were significantly greater in Arm 2 (vaccinated) individuals
173 independent of sex and age, with values that averaged 893.0 units higher than those observed in
174 the unvaccinated group (Arm 1) ($p = 1.41 \times 10^{-5}$). When the analysis was repeated using
175 seropositive samples only (115 Arm 1 samples and 199 Arm 2 samples), the average difference
176 increased to 915.17 units higher in the vaccinated versus unvaccinated group ($p = 1.81 \times 10^{-5}$).
177 Time since last exposure (in months) also demonstrated a significant increase in NAb titer in
178 Arm 2 over Arm 1 (effect size = 319.04, $p = 1.18 \times 10^{-8}$; Figure 2).

179

180 **Discussion**

181 This study aimed to provide the first direct comparison of IgG durability and NAb levels in
182 vaccinated and unvaccinated individuals in a large, prospective, population-wide US sample.
183 Both vaccination against COVID-19 and natural infection with SARS-CoV-2 are associated with
184 seroconversion in most people. However, we found IgG seropositivity was significantly higher,
185 more consistent, and declined less rapidly in vaccinated individuals than in those who were
186 unvaccinated and previously infected with the virus. This pattern was evident one-month post-
187 exposure (the earliest time interval evaluated) and persisted through 12 months post infection or
188 most recent vaccination dose. One possible explanation for the discrepancy between vaccinated

189 and naturally infected groups could be the controlled dose of target antigen provided (indirectly,
190 in many cases) through vaccination, versus the inconsistent “dose” of various viral antigens
191 acquired through natural infection. In a within-subject survival analysis, vaccine-acquired IgG
192 antibodies persisted for up to 12 months (or more) in nearly all cases. This provides within-
193 subject support for strong antibody durability out to 12 months when compared to the vaccinated
194 group (Arm 2) in the cross-sectional analysis. Collectively, these analyses suggest that IgG
195 antibodies raised through vaccination are more reliably durable than those induced by a natural
196 SARS-CoV-2 infection in most individuals. In addition, vaccinated individuals demonstrated
197 higher NAb titers than unvaccinated, previously infected individuals, which prior work has
198 demonstrated as highly predictive of clinical protection against the virus (17).

199
200 Compared to prior research, our estimated rate of seropositivity decline in the unvaccinated
201 group was steeper. Alfego et al. found seropositivity decline to be approximately -0.004% per
202 day, or approximately -0.12% per month (11), while we observed a decline of -0.93% per month.
203 This may be reflective of our smaller sample size or due to an important distinction between each
204 studies’ methods. Alfego et al. evaluated seropositivity from the time of a participant’s first
205 recorded infection (positive diagnostic test) and did not take subsequent exposure events into
206 account, whereas in the current study, we measured seropositivity from the time of the most
207 recent confirmed infection. Nevertheless, the rate of seropositivity decline in the vaccinated
208 cohort was much lower than in the unvaccinated cohort. This holds true whether we compare this
209 rate to those estimates from Alfego et al. or to our own rate estimates for Arm 1 in the present
210 study. Collectively, this suggests that S-protein antibodies raised through vaccination are more
211 reliably durable than those induced by a natural SARS-CoV-2 infection in most individuals.

212
213 While NAb titer is a closer surrogate for immune protection, Anti-S IgG testing offers an
214 advantage in scalability as the requisite immunoassays are less burdensome in terms of time,
215 cost, complexity, and availability than functional NAb assays. Published works by Harvala et al.
216 and Lumley et al. lend support to the clinical relevance of IgG values. The former reported that
217 detection of IgG with the Euroimmun assay highly correlated with NAb titers above 1:100 in
218 convalescent blood samples (27), while the latter observed a connection between S-binding IgG
219 and protection from reinfection with earlier variants of SARS-CoV-2 in previously-infected
220 healthcare professionals followed up to 6 months (18).

221
222 We found that vaccinated individuals showed higher NAb titers than unvaccinated individuals.
223 Given that NAb concentration correlates with protection against infection and severe disease (16,
224 17), our observations suggest that vaccine-acquired immunity may also be more protective than
225 an immune response triggered by natural infection alone. Our findings support similar
226 observations made in Congolese individuals at 2 months post vaccination (with Ad26.COV.2 or
227 BBIP-CorV) compared to 2, 3, or 6 months post natural infection (21). However, whether a
228 vaccine-induced NAb response provides an advantage over the longer term remains unclear. For
229 example, in a previous evaluation of purely vaccine-induced NAb activity in 62 healthcare
230 workers, which excluded cases of prior exposures or breakthrough infections, Decru et al. found
231 significant waning of neutralization activity 10 months after receiving a second dose of
232 BNT162b2 (12). In contrast, here we observed an apparent rise in NAb titer over time (for up to
233 12 months since last reported dose) that was driven predominantly by samples in the vaccinated
234 group. If NAb follows similar patterns as anti-S IgG, it may be that hybrid immunity provides

235 the most durable NAb response. More research is needed to clarify which approach produces the
236 longest enduring neutralization capability. Furthermore, the limitation remains that without more
237 prevailing use of a common reference standard it is difficult to determine what level of titer is
238 necessary for protection, whether that involves full immunity or simply protection from severe
239 disease. In addition, the contribution of other immune factors (e.g., IgA and mucosal immunity)
240 on overall protection should not be overlooked, especially considering those responses may
241 follow different patterns than IgG after vaccination or natural infection.

242
243 One problem that warrants further study is the impact of symptom severity on antibody
244 responses in previously-infected individuals who become vaccinated (hybrid immunity)
245 compared to those who remain unvaccinated, given that binding IgG and NAb responses during
246 and after severe disease are higher functioning and longer lasting than when symptoms are mild
247 (28-30). Future research may also look at the relationships between viral variants and population-
248 wide antibody profiles in vaccinated and unvaccinated cohorts, as well as how antibody
249 characteristics connect to clinical outcomes and transmissibility in each group. Moreover,
250 additional focus should be paid to hybrid immunity and the impact of repeated (or breakthrough)
251 infections and boosters, including extended follow-up (8, 20) for antibody durability and titer
252 beyond one year from each type of exposure in the general population. Flexible study designs
253 that can more easily accommodate adjustments made in response to a rapidly changing viral
254 variant landscape would help future studies maintain relevance over time as SARS-CoV-2
255 transitions from pandemic to endemic circulation.

256

257 *Limitations*

258 The data for Arm 1 are cross-sectional, therefore individual rates of seroreversion could not be
259 evaluated in direct comparison to Arm 2. Additionally, limited sample sizes at later time
260 intervals reduced statistical confidence in some time-specific point estimates of seropositivity,
261 and limited cases with confirmed hybrid immunity prevented us from evaluating those
262 individuals as a separate group. Furthermore, this study relied on self-reported infection and
263 vaccination history, and only took confirmed exposures (those that resulted in a positive
264 diagnostic test) into account. There is a high likelihood that additional exposures to SARS-CoV-
265 2 went undetected and were not reflected in the self-reported COVID-19 diagnostic data;
266 however, we expect that such events would have inflated serology values most frequently in the
267 unvaccinated group. As such, these findings give a conservative estimate of the differences
268 between vaccination and natural infection in terms of antibody response. Finally, our study
269 largely coincided with circulation of the Delta variant, and reflected immune responses triggered
270 by exposure to Alpha, Beta, or Delta variants in previously-infected individuals. The Omicron
271 (BA.1) variant was discovered as this study concluded and has exhibited greater transmissibility
272 than previous variants due to a highly mutated spike protein and consequent immune evasion and
273 increased receptor affinity (31). Subsequent sublineages (BA.1.1, BA.2, BA.3, BA.4, and BA.5)
274 have since been identified and show similar or greater transmissibility and evasion of antibodies
275 compared to the parent variant (32, 33). Furthermore, a new vaccine formulation that offers more
276 protection against Omicron has been made available as a booster dose. It is uncertain how
277 combinations of variant/subvariant exposures and primary/booster vaccine formulations may
278 affect immune responses acquired through natural infection, vaccination, or hybrid exposure in a
279 rapidly shifting landscape that continues to challenge the pace of science.
280

281 **Conclusions**

282 This study was one of the first to directly compare population-level antibody durability acquired
283 through vaccination or natural infection in a nationwide sample and supports the conclusion that
284 completing the primary series of vaccination triggers a more durable and protective antibody
285 response compared to a known single infection with early variants of SARS-CoV-2. This study
286 further supports the importance of broad vaccination campaigns over relying upon natural,
287 infection-driven herd immunity alone in the fight against SARS-CoV-2. Future work
288 investigating antibody profiles resultant to booster doses, hybrid immunity, as well as repeat and
289 variant specific infections are critical in our continued understanding of SARS-CoV-2 and
290 COVID-19.

291

292 **Abbreviations**

293 COVID-19: Coronavirus Disease 2019

294 DBS: dried blood spot

295 IgG: Immunoglobulin G

296 IQR: Interquartile range

297 NAb: Neutralizing antibody

298 NT50: NAb titers at 50% inhibition

299 US: United States

300 WHO: World Health Organization

301

302 **Declarations**

303 *Ethics approval and consent to participate*

304 This protocol was approved by WCG IRB (IRB registration #20210763). All participants
305 provided written informed consent prior to enrollment in the study.

306

307 *Consent for publication*

308 Not applicable.

309

310 *Availability of data and materials*

311 The datasets used and/or analyzed during the current study are available from the corresponding
312 author on reasonable request.

313

314 *Competing interests*

315 Kaylan Olds, Devon Humphreys, Kathleen Gavin, and Timothy Bauer are full time employees of
316 Everly Health, Inc. Anne Wylie has no conflicts to report.

317

318 *Funding*

319 This study was funded and conducted by Everly Health, Inc.

320

321 *Authors' contributions*

322 KMO: Had a role in study conception, data interpretation, and drafted the work, DPH: Had a role
323 in study conception, performed data analysis and interpretation, and assisted in drafting the work,

324 KMG: Performed data interpretation and assisted in drafting the work, ALW: Had a role in data

325 analysis, data interpretation, and assisted in drafting the work, TAB: Led study conception, data

326 interpretation, and assisted in drafting the work. All authors have reviewed and

327 approved this submitted version of the manuscript.

328

329 *Acknowledgements*

330 The authors thank PerkinElmer Genomics, Inc. and SpearBio, Inc. for providing in-kind support
331 with serology testing.

332

333 **References**

334 1. Iboi EA, Ngonghala CN, Gumel AB. Will an imperfect vaccine curtail the COVID-19
335 pandemic in the U.S.? *Infect Dis Model.* 2020;5:510-24.

336 2. Shah SMA, Rasheed T, Rizwan K, Bilal M, Iqbal HMN, Rasool N, et al. Risk
337 management strategies and therapeutic modalities to tackle COVID-19/SARS-CoV-2. *J Infect*
338 *Public Health.* 2021;14(3):331-46.

339 3. Kreps S, Prasad S, Brownstein JS, Hswen Y, Garibaldi BT, Zhang B, et al. Factors
340 Associated With US Adults' Likelihood of Accepting COVID-19 Vaccination. *JAMA Netw*
341 *Open.* 2020;3(10):e2025594.

342 4. Ball P. Anti-vaccine movement could undermine efforts to end coronavirus pandemic,
343 researchers warn. *Nature.* 2020;581(7808):251.

344 5. Szilagyi PG, Thomas K, Shah MD, Vizueta N, Cui Y, Vangala S, et al. National Trends
345 in the US Public's Likelihood of Getting a COVID-19 Vaccine-April 1 to December 8, 2020.
346 *JAMA.* 2020.

347 6. Goldberg Y, Mandel M, Bar-On YM, Bodenheimer O, Freedman LS, Ash N, et al.
348 Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2. *N Engl J Med.*
349 2022;386(23):2201-12.

- 350 7. Amirthalingam G, Bernal JL, Andrews NJ, Whitaker H, Gower C, Stowe J, et al.
351 Serological responses and vaccine effectiveness for extended COVID-19 vaccine schedules in
352 England. *Nat Commun.* 2021;12(1):7217.
- 353 8. Predecki M, Clarke C, Brown J, Cox A, Gleeson S, Guckian M, et al. Effect of previous
354 SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine.
355 *Lancet.* 2021;397(10280):1178-81.
- 356 9. Payne RP, Longet S, Austin JA, Skelly DT, Dejnirattisai W, Adele S, et al.
357 Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine. *Cell.*
358 2021;184(23):5699-714.e11.
- 359 10. McDade TW, Sancilio A, D'Aquila R, Mustanski B, Vaught LA, Reiser NL, et al. Low
360 Levels of Neutralizing Antibodies After Natural Infection With Severe Acute Respiratory
361 Syndrome Coronavirus 2 in a Community-Based Serological Study. *Open Forum Infect Dis.*
362 2022;9(3):ofac055.
- 363 11. Alfego D, Sullivan A, Poirier B, Williams J, Adcock D, Letovsky S. A population-based
364 analysis of the longevity of SARS-CoV-2 antibody seropositivity in the United States.
365 *EClinicalMedicine.* 2021;36:100902.
- 366 12. Decru B, Van Elslande J, Steels S, Van Pottelbergh G, Godderis L, Van Holm B, et al.
367 IgG Anti-Spike Antibodies and Surrogate Neutralizing Antibody Levels Decline Faster 3 to 10
368 Months After BNT162b2 Vaccination Than After SARS-CoV-2 Infection in Healthcare
369 Workers. *Front Immunol.* 2022;13:909910.
- 370 13. Yang Y, Yang M, Peng Y, Liang Y, Wei J, Xing L, et al. Longitudinal analysis of
371 antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months
372 after infection. *Nat Microbiol.* 2022;7(3):423-33.

- 373 14. Wang Z, Muecksch F, Schaefer-Babajew D, Finkin S, Viant C, Gaebler C, et al.
374 Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. *Nature*.
375 2021;595(7867):426-31.
- 376 15. Pérez-Alós L, Armenteros JJA, Madsen JR, Hansen CB, Jarlhelt I, Hamm SR, et al.
377 Modeling of waning immunity after SARS-CoV-2 vaccination and influencing factors. *Nat*
378 *Commun*. 2022;13(1):1614.
- 379 16. Addetia A, Crawford KHD, Dingens A, Zhu H, Roychoudhury P, Huang ML, et al.
380 Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a
381 Fishery Vessel Outbreak with a High Attack Rate. *J Clin Microbiol*. 2020;58(11).
- 382 17. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al.
383 Neutralizing antibody levels are highly predictive of immune protection from symptomatic
384 SARS-CoV-2 infection. *Nat Med*. 2021;27(7):1205-11.
- 385 18. Lumley SF, O'Donnell D, Stoesser NE, Matthews PC, Howarth A, Hatch SB, et al.
386 Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers. *N Engl J*
387 *Med*. 2021;384(6):533-40.
- 388 19. Clarke KEN, Jones JM, Deng Y, Nycz E, Lee A, Iachan R, et al. Seroprevalence of
389 Infection-Induced SARS-CoV-2 Antibodies - United States, September 2021-February 2022.
390 *MMWR Morb Mortal Wkly Rep*. 2022;71(17):606-8.
- 391 20. Arkell P, Gusmao C, Sheridan SL, Tanesi MY, Gomes N, Oakley T, et al. Serological
392 surveillance of healthcare workers to evaluate natural infection- and vaccine-derived immunity
393 to SARS-CoV-2 during an outbreak in Dili, Timor-Leste. *Int J Infect Dis*. 2022;119:80-6.


- 394 21. Batchi-Bouyou AL, Djontu JC, Vouvougui JC, Mfoutou Mapanguy CC, Lobaloba
395 Ingoba L, Mougany JS, et al. Assessment of neutralizing antibody responses after natural SARS-
396 CoV-2 infection and vaccination in congolese individuals. *BMC Infect Dis.* 2022;22(1):610.
- 397 22. Bonura F, Genovese D, Amodio E, Calamusa G, Sanfilippo GL, Cacioppo F, et al.
398 Neutralizing Antibodies Response against SARS-CoV-2 Variants of Concern Elicited by Prior
399 Infection or mRNA BNT162b2 Vaccination. *Vaccines (Basel).* 2022;10(6).
- 400 23. Altarawneh HN, Chemaitelly H, Ayoub HH, Tang P, Hasan MR, Yassine HM, et al.
401 Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections. *N Engl J*
402 *Med.* 2022;387(1):21-34.
- 403 24. Gazit S, Shlezinger R, Perez G, Lotan R, Peretz A, Ben-Tov A, et al. SARS-CoV-2
404 Naturally Acquired Immunity vs. Vaccine-induced Immunity, Reinfections versus Breakthrough
405 Infections: a Retrospective Cohort Study. *Clin Infect Dis.* 2022.
- 406 25. Lumley SF, Rodger G, Constantinides B, Sanderson N, Chau KK, Street TL, et al. An
407 Observational Cohort Study on the Incidence of Severe Acute Respiratory Syndrome
408 Coronavirus 2 (SARS-CoV-2) Infection and B.1.1.7 Variant Infection in Healthcare Workers by
409 Antibody and Vaccination Status. *Clin Infect Dis.* 2022;74(7):1208-19.
- 410 26. Hall V, Foulkes S, Insalata F, Kirwan P, Saei A, Atti A, et al. Protection against SARS-
411 CoV-2 after Covid-19 Vaccination and Previous Infection. *N Engl J Med.* 2022;386(13):1207-
412 20.
- 413 27. Harvala H, Robb ML, Watkins N, Ijaz S, Dicks S, Patel M, et al. Convalescent plasma
414 therapy for the treatment of patients with COVID-19: Assessment of methods available for
415 antibody detection and their correlation with neutralising antibody levels. *Transfus Med.*
416 2021;31(3):167-75.

- 417 28. Legros V, Denolly S, Vogrig M, Boson B, Siret E, Rigail J, et al. A longitudinal study of
418 SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and
419 COVID-19 severity. *Cell Mol Immunol.* 2021;18(2):318-27.
- 420 29. Rijkers G, Murk JL, Wintermans B, van Looy B, van den Berge M, Veenemans J, et al.
421 Differences in Antibody Kinetics and Functionality Between Severe and Mild Severe Acute
422 Respiratory Syndrome Coronavirus 2 Infections. *J Infect Dis.* 2020;222(8):1265-9.
- 423 30. Scheiblauer H, Nübling CM, Wolf T, Khodamoradi Y, Bellinghausen C, Sonntagbauer
424 M, et al. Antibody response to SARS-CoV-2 for more than one year - kinetics and persistence of
425 detection are predominantly determined by avidity progression and test design. *J Clin Virol.*
426 2022;146:105052.
- 427 31. McCallum M, Czudnochowski N, Rosen LE, Zepeda SK, Bowen JE, Walls AC, et al.
428 Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement. *Science.*
429 2022;375(6583):864-8.
- 430 32. Maxmen A. Why call it BA.2.12.1? A guide to the tangled Omicron family. *Nature.*
431 2022;606(7914):446-7.
- 432 33. Yao L, Zhu KL, Jiang XL, Wang XJ, Zhan BD, Gao HX, et al. Omicron subvariants
433 escape antibodies elicited by vaccination and BA.2.2 infection. *Lancet Infect Dis.*
434 2022;22(8):1116-7.
- 435
- 436
- 437
- 438
- 439

440 **Figures**

441 Figure 1. Anti-S1 seropositivity in unvaccinated/naturally infected (Arm 1) and vaccinated (Arm

442 2) groups




443

444

445

446

447 Figure 2. NAb titer in unvaccinated/naturally infected (Arm 1) and vaccinated (Arm 2) groups



448